- Medicine Name: Evenity
- API: Romosozumab-aqqg
- Dosage Form & Strength: Injections: 105 mg/1.17 mL solution in a single-use prefilled syringe
- Manufactured By: Amgen Inc.
Evenity (romosozumab-aqqg) is a sclerostin inhibitor used for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or those who have failed or are intolerant to other existing osteoporosis therapy.
Recommended Dosage: The recommended dosage of Evenity is 210 mg administered subcutaneously in the abdomen, thigh, or upper arm. Administer the medicine once every month. The treatment duration for Evenity is 12 monthly doses. Patients should be adequately supplemented with calcium and vitamin D during treatment. If any dose is missed, administer as soon as it can be rescheduled. Thereafter, the dose can be scheduled every month from the date of the final dose.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.